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Objectives: In 2009, Greece entered into one of the most serious economic down-
turns in its modern history. In May 2010, the country was put under the supervi-
sion of Troika (EU, ECB and IMF). Retail pharmaceutical market with size c. a. € 6.5 
bn in retail prices for 2009 (public pharmaceutical expenditure € 5.2 bn), was one 
of the main targets for change through the implementation of new policies and 
drastic spending cuts. The purpose of this study was to measure the impact that 
these new policies for pharmaceutical spending had and how this was attributed 
to the levers of price, market volume and product mix. MethOds: An economic 
model was used, based on IMS Hellas’ and Hellenic Statistical Authority data, 
to measure the contribution that (a) price; (b) market volume; and (c) product 
mix had on the reduction in the size of the retail market for pharmaceuticals in 
the period 2009-2014. The detailed approach decomposes the market change, as 
measured in values, into those attributed to (a) price (assuming market volume 
and product mix are constant); (b) market volume (assuming prices and product 
mix are unchanged); (c) product mix. Results: The analysis indicated that, the 
major contributor in the reduction of the pharmaceutical market size was the 
price of medicines. It has been estimated that 87% of the reduction (> € 1.2 bn) is 
coming from price. Volume contributed an additional c. a. 38% (> € 0.5 bn) in the 
reduction of the size but, at the same time, it was partially offset from substitu-
tion with pricier medicines. cOnclusiOns: Price was the major driver for the 
reduction in the size of the retail pharmaceutical market during the period of 
crisis. Volume had an impact as well but it was partially offset by switch towards 
more expensive medicines.
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Objectives: The “liste-en-sus” was implemented within the framework 
of the HPST [1] law. One of its objectives was to ensure access to highly-priced 
innovative medicines in hospital settings without distorting the Diagnostic-
Related Groups (DRG). The objective of this research is to analyse the degree of 
innovation of the medicines included in the “liste-en-sus”. MethOds: Starting 
from the ATIH [2] database, an initial analysis consisted of identifying all the 
Health Technology Assessments (HTAs) for each product included in the “liste-
en-sus” available on the HAS website [3] . Then, for each HTA, the following infor-
mation was collected: assessment date, SMR [4] and ASMR [5] scores. Results: 
The liste-en sus includes 123 medicines. 21% have no HTA available. Another 19% 
were last evaluated before 2004. Among the medicines which had undergone an 
HTA since 2004, 7% were granted an ASMR I, 27% an ASMR II, 22% an ASMR III, 
8% an ASMR IV, 36% an ASMR V. In other terms, amongst the medicines which 
have undergone an HTA in the last 10 years, about 45% of them were deemed 
non-innovative (ASMR IV/V). Those medicines mainly consist in antihemorrhagics 
(27%), antianaemics (18%), antineoplastics (15%) and immune sera and immuno-
globulins (15%)[6] . Although they are not innovative, those medicines are only 
used in a proportion of patients and are thus likely to distort DRG. To put these 
results into perspective, since 2005, 92% of evaluated medicines were granted an 
ASMR IV/V [7]. cOnclusiOns: Looking at the list-en-sus’ objectives, the most 
decisive criterion seems to be more stability of the DRG rather than access to 
innovative medicines; however a higher proportion of the medicines in the liste-
en-sus are innovative.
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Objectives: To establish the key policy areas that will drive the establishment 
of a sustainable biosimilar medicines market. To outline the benefits that these 
will bring to Physicians, Payers, Patients, and Industry, with particular focus 
on the benefits for European National Health systems. MethOds: 71 qualita-
tive in-depth interviews were conducted across 7 European markets: France, 
Germany, Hungary, Italy, Poland, Spain and the UK, collecting insight from 
experts and policy influencers at pan-European, National and Regional levels, 
Physicians, Payers, Pharmacists, Patients, and Industry. Quantitative modelling 
used a systems dynamics approach with in-depth analysis of 3 representative 
biologic products: trastuzumab, bevacizumab, and adalimumab. Dynamics were 
based on a delphi panel of expert opinions. The five forces of supplier power, buyer 
power, impact of new entrants, impact of substitutes, and competitive rivalry 
were addressed. A ranking of the attractiveness of policy combinations from a 
sustainability and benefit perspective was made based on a biosimilar medicines 
market “Sustainability Index” and the calculation of the magnitude of the ben-
efits (cost savings, additional patients treated) that the policy combination was 
likely to produce. Results: The qualitative analysis has shown that a European 
biosimilars medicines market based on stakeholder and policy alignment in four 
key areas (1. education and understanding, 2. experience and use, 3. sustainable 
pricing, 4. rational decision making) will be sustainable and deliver benefits to 
all stakeholders. The quantitative analysis demonstrated that the most efficient 
policy combination, measured in terms of the sustainability index, was the same 
for all 3 molecules and would deliver cumulative 10 year cost savings of between 
24% and 26%. cOnclusiOns: Greater stakeholder alignment and the combina-
tion of specific policies will increase the sustainability of the European biosimilar 
medicines market. A sustainable biosimilar medicines market will deliver signifi-
cant benefits to all stakeholders.
security funding law, France is becoming the first country to allow biosimilars sub-
stitution when initiating treatment course. To encourage biosimilars substitution, 
the Norwegian Medicines Agency announced in 2013 the funding of clinical studies 
with infliximab originator and biosimilars in which patients would be switched 
from originator to biosimilars forth and back. Moreover, increased price discounts 
of about 40% were applied for infliximab in Norway. By 2020, expected savings 
for biosimilars are estimated around € 12-33 billion in big EU5, Poland, Romania, 
Sweden. cOnclusiOns: While patent cliff of major biologic drugs is expected on 
the next 5 years, initiatives to reassure physicians to prescribe biosimilars and 
implementation of substitution rules, even if still raising some reluctance, might 
contribute to boost biosimilar uptake in Europe. Price competition will impose 
manufacturers of branded biologics to adopt new pricing strategies.
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Objectives: In Turkey, a medicine reference pricing system has been in use since 
2004. The price of pharmaceuticals is determined by the acceptance of the lowest 
ex-factory price in the reference countries (Greece, France, Italy, Portugal, Spain). We 
aimed to examine the first 100 medicine’s, having the annual maximum amount 
on the average Turkish Lira (TL) based medicine sales between the years 2008-2013 
which have 25.1% value in the total pharmaceutical market, reference price changes 
in these period. MethOds: While pharmaceutical sales data were obtained from 
the IMS Health-Turkey data base, medicine prices were obtained from the Medicine 
Price List published by Turkish Medicines and Medical Devices Agency. Results: In 
2008, the top 100 medicines in determining the price of most of Italy were taken as 
the reference country, followed by Spain and Greece. In 2013 while Greece is taken as 
the reference country more common; France and Italy are to follow. In 2008, only one 
medicine’s price increased, and only one medicine’s price decreased because of the 
reference price. In 2009 and 2010 price increases did not seen. In 2009, 8 and in 2010, 
30 medicines prices had decreased. In 2011, 2012 and 2013 totally 27 medicines refer-
ence prices had increased. 21 medicine’s price in 2011, 20 medicine’s price in 2012 
and 24 medicine’s price in 2013 had decreased. While mostly France (13 medicines) 
connected to the reference price increases, mostly Greece (58 medicines) has been 
based reference price drop in the analyzed period. cOnclusiOns: The application 
of reference prices, medicine prices to be reduced to a large extent. Greece based 
reference price decreases are observed to be mainly from the year 2010. The reason 
for this is considered as the economic crisis in Greece and the agreement with the 
IMF, EU and ECB, the Greek government at cost-containment.
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Objectives: External price referencing (EPR) is a method to control pharmaceutical 
prices, wherein decision-makers specify a basket of countries, whose prices they 
use to inform their national target price. EPR is practiced frequently worldwide, 
though countries vary substantially in how they execute EPR. The objective of our 
pioneer collaborative health policy research initiative was to analyse how EPR is 
used in Middle East countries, and assess whether EPR results in narrower price cor-
ridor for innovative pharmaceuticals compared to non-pharmaceutical services not 
subjected to EPR. MethOds: In Q1 2014, we conducted a survey on EPR regulations, 
and collected prices of 16 innovative pharmaceuticals and 10 non-pharmaceutical 
services in six Middle East countries (Egypt, Jordan, Kuwait, Lebanon, Saudi Arabia, 
UAE). Prices in local currency were converted to USD by using market exchange 
rates. Maximum and minimum prices of each pharmaceutical and non-pharmaceu-
tical technology were compared to mean prices in the study countries. Results: 
EPR regulations are most stringent in Egypt and Saudi Arabia (largest study coun-
tries), mandating the lowest pharmaceutical price out of a basket comprising more 
than 25 countries each. By contrast, Kuwait references the country of origin only. The 
average price corridor is +/-38% for pharmaceuticals and +/-78% for outpatient and 
hospital services compared to mean prices. cOnclusiOns: EPR results in narrower 
price corridor for innovative pharmaceuticals compared to other health care ser-
vices. Prices of innovative pharmaceuticals are the lowest in Egypt and Saudi Arabia, 
and the highest in Kuwait, indicating the importance of population size and EPR 
implementation on drug price levels. However, EPR results in higher pharmaceutical 
prices in lower income countries compared to non-pharmaceutical services, which 
may limit timely access of patients to new medicines in these countries compared 
to global markets. Stakeholders should understand the implications of EPR and 
develop solutions to prevent its negative consequences.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. The objective 
of this analysis is to to understand the impact of selected 5 major policy changes 
by MoH to sales of locally manufactured and imported pharmaceutical products in 
the respective periods. MethOds: 132 months sales data with segmented regres-
sion analysis for interrupted time series were used. International reference pricing 
of pharmaceuticals (RF), mandatory reimbursement dossier submission for new 
molecules, new indications and line extensions with medical and economic evalu-
ations (MRDS), auditing for good manufacturing practice (GMP), family physician 
system (FP) and compulsory medical service for physicians (CMS) were selected as 
five major policies that may affect cost, demand and supply of pharmaceuticals. 
The analysis was conducted for total imported pharmaceutical (IP) sales and total 
locally manufactured pharmaceutical (LMP) sales. The Durbin-Watson d statistics 
of SPSS version 20.0 was used as serial correlation. Shift in slope with p< 0.05 was 
considered as statistically significant. Results: The negative effect of RF policy 
change on CS trends was more prominent for IP than LMP sales. However, the shift 
in CS due to other 4 policy changes was lower for IP when compared with LMP 
sales. The differences reached statistical significance level except for CMS policy. 
Although not significant, positive shift of US due to RF policy change was higher for 
LMP than IP sales. There was a decreasing slope of LMP unit sales following MRDS 
and GMP policies but an increasing slope of IP unit sales. cOnclusiOns: Policy 
changes may effect at differently direction and amount the unit and cost sales 
of LMPs and IPs. Cost control mechnism such as RF has a more negative effect on 
imported product as expected.
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Objectives: This study intends to provide an overview of the US biosimilar poli-
cies and its impact on the development of the biosimilar market in this coun-
try. MethOds: A literature review was conducted from the US Food and Drug 
Administration (FDA) website, Generics and Biosimilars Initiative (GaBi) web-
sites, Medline® database, and available grey literature. Results: The Biologics 
Price Competition and Innovation Act (2009) established an abbreviated Biologic 
License Application (aBLA) pathway/351 (k) for biosimilars in addition to the 1. 
Non-abbreviated biologic license application (BLA) /351 (a); 2. New Drug Application 
(NDA) /505 (b) (2); or 3. Abbreviated New Drug Application (ANDA). 10 follow-on 
biologics under NDA/ANDA and one under BLA were previously approved. Product 
identity and therapeutic equivalence of some biologics (i. e. Lovenox, Copaxone) led 
to important debates for defining the application pathway. Currently, the FDA has no 
351 (k) approvals. The lack of clear FDA guidance on data requirements for biosimi-
larity in aBLA was a limiting factor for manufacturers to go through aBLA pathway. 
They preferably opted for a classical BLA pathway due to its longer exclusivity period 
and nearly the same amount of data required (i. e. Neutroval). The impact of the 
recently released FDA draft guidance on designing clinical studies for biosimilar-
ity (5/13/14) is yet to be seen but should address issues on proving biosimilarity 
in aBLA. Further debate is anticipated but an increase in applications is expected 
and biosimilars savings are projected at $250 billion by 2024. cOnclusiOns: 
The biosimilars market is still lagging, specifically compared to the EU, with no 
351 (k) approvals despite the US’ leading position in the biopharmaceuticals market. 
However, the US’ high prices for innovative products and history of generic utiliza-
tion can signify a positive market projection after a transition period, as was seen 
in Germany and Sweden. Further, the new FDA guidance by addressing biosimilarity 
issues may ease biosimilar market entry.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. Total phar-
maceutical market reached US $ 8 billion in last 10 years. The objective of this 
analysis is to understand the impact of selected 5 major policy changes by MoH 
on the growth locally manufactured and imported pharmaceutical markets of top 
selling ATC1 phramaceutical group, which was Alimentary and Metabolism (A0) 
with US $ 1.1 billion sales in 2012, in the respective periods in Turkey. MethOds: 
132 months sales data with segmented regression analysis for interrupted time 
series were used. International reference pricing of pharmaceuticals (RF), manda-
tory reimbursement dossier submission for new molecules, new indications and 
line extensions with medical and economic evaluations (MRDS), auditing for good 
manufacturing practice (GMP), family physician system (FP) and compulsory medi-
cal service for physicians (CMS) were selected as five major policies that may affect 
cost, demand and supply of pharmaceuticals. We analyzed possible breaks in trends 
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of 
health including pharmaceutical sales by improving access to health services. 
Total pharmaceutical market reached US $ 8 billion in last 10 years. The objective 
of this study is to understand the differences in the impact of selected 5 policies 
on 5 top selling ATC1 groups in terms of cost sales (CS) in the respective peri-
ods. MethOds: 132 months sales data with segmented regression analysis for 
interrupted time series were used. International reference pricing of pharmaceu-
ticals (RF), mandatory reimbursement dossier submission for new molecules, new 
indications and line extensions with medical and economic evaluations (MRDS), 
auditing for good manufacturing practice (GMP), family physician system (FP) 
and compulsory medical service for physicians (CMS) were selected as five major 
policies that may affect cost, demand and supply of pharmaceuticals. We analyzed 
possible breaks in trends prior and after the implementation of 5 selected policies 
of the HTP. The Durbin-Watson d statistics of SPSS version 20.0 was used as a test 
for serial correlation of error terms. Shift in slope with p< 0.05 was considered 
as statistically significant. Results: There was an increasing trend for all ATC1 
groups prior the implementation of policies. The trends in systemic antienfec-
tives (J0), alimentary and metabolism (A0) and Respiratory system (R0) Central 
Nerveous System (N0) groups were negatively impacted from all policies except for 
RF. All policies impacted negatively the trend in cardiovascular system (C0) group. 
Implementation of RF had a significant positive impact on A0 and R0 group. Impact 
of RF was positive on C0 however it did not reach signifcance level. cOnclusiOns: 
Policy changes were very successful to control growth of top selling pharmaceuti-
cal groups while improving access to health. RF and CMS policies were the least 
effective cost containment measures
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Objectives: To compare the savings achieved by appraisal of the clinical and cost 
effectiveness of individual drugs by NICE’S Technology Appraisals for England & 
Wales with those due to price cuts under the Pharmaceutical Pricing Regulation 
Scheme 2000-2014. MethOds: Maximum and best estimates of savings attributable 
to the 512 technologies appraised and published by NICE to end 2013 with published 
reports of the PPRS. Published estimates of the cost of the Multiple Risk Sharing 
Scheme, the Cancer Drugs Fund and the End-of-Life criteria. Results: Savings 
attributable to NICE were relatively low. Few drugs were not recommended and of 
these, special schemes, funds and exceptions required by the governments of the 
day, reduced savings that might otherwise have resulted. The bulk of the savings 
due to NICE resulted from price cuts under Patient Access Schemes from 2009. 
Higher savings resulted from cross the board price cuts in the PPRS. cOnclusiOns: 
Health systems aiming to control pharmaceutical expenditure should consider both 
individual level appraisal of drugs as overall budget control of the branded prescrip-
tion drugs budget.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. The top 100 medicines, annual average highest 
amount of sales of between 2008-2013, had one to four of the total pharmaceuti-
cal market value in 2013. We aimed to examine the status of original and generic 
medicines in the first 100 medicine’s and evaluate the effects of policy interven-
tions on these medicine sales. MethOds: While pharmaceutical sales data were 
obtained from the IMS Health-Turkey data base, prices and characteristics of medi-
cines were obtained from the Turkish Medicine and Medical Devices Agency data 
bases. Each group (original/generic medicines) was analyzed using TRAMO and 
SEATS method. Results: 78 medicines are original, 22 medicines are generic. In 
2009 compared to the previous year both generic and original medicine spending 
increased by respectively 16% and 20,9%. Between the years 2010-2012 compared 
to the previous year both generic and original medicines spending decreased by 
different ratios. In 2013 according to 2012, generic medicine spending decreased 
by 8.3% but original medicine spending increased by 7.9%. In 2013 total original 
medicine spending was 2888 million Turkish Liras (TL). This amount estimated to 
be 3050 million TL in 2014 and 3145 million TL in 2015. Generic medicines total 
spend was 501 million TL in 2013. This amount projected to be 510 million TL in 
2014 and 515 million TL in 2015. cOnclusiOns: Original medicines dominated the 
top 100 medicines. The total effect of the intervention is more negatively in generic 
medicines. At the end of 2013, it is understood that original medicines total amount 
have a tendency to increase.
